Nevertheless, the rapid evolvement of this novel drug class has pushed forward the mechanistic obesity research [4,8] and exposed novel anti-obesity targets such as the modulation of key effectors of the phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/phosphodiesterase (PDE) signaling pathway [9,10,11]. The gene discussed is AKT1; the disease is obesity due to melanocortin 4 receptor deficiency.